Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from SONN

This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?

Sonnet Bio is pivoting towards becoming a crypto treasury company by accumulating the HYPE Crypto.

Barchart · Aug 4, 2025

Palantir, The Trade Desk, Tilray, Sonnet Biotherapeutics, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks traded mostly flat on Monday as investors reacted to President Donald Trump’s announcement of a 30% tariff on all imports from the EU and Mexico, effective August 1. Inflation worries ahead of Tuesday's CPI data also weighed on sentiment. By the close, the Dow rose 0.2% to 44,459.65,…

Benzinga · Jul 15, 2025

Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns

Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) stock experienced a drop of 5.54% on Thursday, followed by a remarkable recovery of 14.29% in after-hours trading.

Benzinga · Jul 4, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Is This Biotech Stock a Rising Star in the Making?

Shares of oncology-focused biotechnology company Sonnet BioTherapeutics (SONN) have plummeted more than 70% in price year-to-date due to its poor financials and the broad-based market sell-off. However, the company is advancing its drug candidates via research breakthroughs, clinical trials, and strategic initiatives. Given the company’s constant progress, can this biotech…

StockNews.com · Nov 9, 2022

Sonnet Shares Surge As FDA Clears Its First Human Trial For Solid Tumor Candidate

The FDA has signed off Sonnet BioTherapeutics Holdings Inc's (NASDAQ:SONN) Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) technology. Sonnet will initiate its First-in-Human Phase 1 trial in adult oncology patients in Q2 of 2022. The study will establish…

Benzinga · Mar 16, 2022

Coverage From

People

Donald Trump

216,406 stories

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.